US President Donald Trump has announced a new tariff plan for imported generic medicines. The tariffs will not begin immediately. Instead, imported generic drugs will continue to enter the US without any tariff for the next two years. After that, the tariff will jump to 100% for one year and then rise to 200% from August 2029. Trump says the aim is simple: force pharmaceutical companies to manufacture medicines inside the US instead of importing them. But what exactly has Trump announced? Why is India watching this move so closely? Will medicine prices rise in the US? Could Indian pharmaceutical companies lose business? We answer these questions in today’s explainer. What has Trump announced? Trump unveiled a phased tariff plan on imported generic medicines. This means the duties will increase gradually instead of all at once. The timeline looks like this: Trump wrote on Truth Social: “This is done in order to reshore generic pharmaceutical production into America.” He added: “The objective of this policy is to protect the people of the United States.” Meanwhile, the existing policy for patented and innovative medicines will continue unchanged. Why does Trump want these tariffs? Trump says the US depends too much on imported medicines. According to his administration, that creates two problems. First, the US remains vulnerable if overseas supply chains are disrupted. Second, American manufacturing loses investment and jobs. The White House wants companies to build factories inside the US instead. This means overseas manufacturers now have about two years to decide whether to shift production or continue exporting and eventually pay much higher tariffs. What are generic medicines? Generic medicines are cheaper versions of branded drugs. They contain the same active ingredient and work in the same way as the original medicine after patent protection expires. For example: A branded blood pressure medicine may cost several times more. Once its patent expires, several companies can produce a generic version at a much lower price. Today, generic medicines account for most prescriptions filled in the US. That is why any major change in their supply chain can affect millions of patients. Why is India paying close attention? India is one of the world’s biggest producers of generic medicines. The country supplies around 30% of the world’s generic medicines, according to the Union Health Ministry. It is also among the largest suppliers to the US market. Many Indian pharmaceutical companies manufacture medicines in India and export them to America. If tariffs rise to 100% and later 200%, exporting directly to the US could become far more expensive. Companies may have to: This could affect investment decisions across India’s pharmaceutical sector. Could medicine prices rise in the US? Possibly, but not immediately. Everything depends on how pharmaceutical companies respond. There are three possibilities: However, the actual impact will depend on how quickly US-based production expands. Has Trump targeted pharmaceutical imports before? Yes. Earlier this year, the Trump administration imposed tariffs on patented pharmaceutical products and some related ingredients. At that time, generic medicines and biosimilars were exempt. A biosimilar is a medicine that is highly similar to an existing biological drug and works in the same way. The administration had said the exemption would be reviewed later. The latest announcement extends Trump’s tariff policy to generic medicines as well. Why has the US given companies two years? The government recognises that pharmaceutical manufacturing cannot be relocated overnight. Building a medicine manufacturing plant involves: These processes often take several years. The two-year zero-tariff period gives companies time to decide whether to invest in US facilities. What does this mean for Indian pharmaceutical companies? Indian exporters now face an important strategic decision. Some may continue exporting from India until tariffs begin. Others may accelerate investment in US manufacturing. At the same time, Indian companies are also looking beyond the US. Recently, the India-UK Comprehensive Economic and Trade Agreement (CETA) removed tariffs on nearly all traded products. Industry body Pharmexcil expects this to improve the competitiveness of Indian medicines in the UK. This suggests Indian exporters may increasingly diversify into other markets while maintaining their US presence. At present, Trump has announced the policy framework. The administration is expected to issue detailed rules explaining: How compliance will be monitored. Only after these notifications are released will companies know the full impact. What does this indicate politically? The announcement fits Trump’s broader ‘America First’ trade strategy. He has repeatedly used tariffs to encourage companies to manufacture inside the US. In recent weeks, he has also announced new tariffs on products from countries including Brazil and Canada. This suggests pharmaceutical imports have become another focus of his broader manufacturing policy. What happens next? For now, imported generic medicines will continue to enter the US without tariffs until July 2028. The real decisions will now be taken by pharmaceutical companies. They must decide whether building factories in the US is cheaper than paying tariffs that could eventually reach 200%. For India, the announcement is significant because the US remains one of its largest pharmaceutical export markets. Whether the tariffs reshape global medicine supply chains will depend on how companies respond over the next two years, and on the detailed rules the US administration issues before the policy takes effect. Post navigation Messi’s ₹8,000 crore magical leg insurance policy is world’s ‘costliest’:Which other celebrities insured body parts for how much amount?
